Optimum minimization strategies in hepatitis C virus infected liver transplant

Current Opinion in Organ Transplantation

Volumn 12, Issue 6, 2007, Pages 641-646

  Melero, Josep L ^a   Berenguer, Marina ^a,b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b University Medical   (Spain)

Author keywords

Cyclosporine; Mycophenolate mofetil; Sirolimus; Steroids; Tacrolimus

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

CHOLESTATIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG INHIBITION; DRUG WITHDRAWAL; GRAFT REJECTION; HEALTH CENTER; HISTOPATHOLOGY; HISTORY OF MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NONHUMAN; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; SURVIVAL; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

EID: 36248937620     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3282f1fbd9     Document Type: Review

References (46)

1. Berenguer M. Hepatitis C and Liver transplantation. Current Opinion in Organ Transplantation 2005; 10:81-89.
2. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001; 35:666-678.
3. Wiesner RH, Sorrell M, Villamil F. Report of the first international liver transplant society consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9 (Suppl 3):S1-S9.
4. Samuel D, Forns X, Berenguer M, et al. Report of the Monothematic EASL Conference on Liver Transplantation for Viral Hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006; 45:127-143. This meeting was the last large conference on the management of patients with HCV and HBV infection after liver transplantation with recommendations issued by international experts.
5. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36:202-210.
6. Neumann UP, Berg T, Bahra M, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77:226-231.
7. Forman LM, Dewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122:889-896.
8. Berenguer M, Crippin J, Gish R, et al. A model to predict severe HCV related disease following liver transplantation. Hepatology 2003; 38:34-41.
9. Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8:362-369.
10. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation. J Hepatol 2005; 42:448-456.
11. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51:248-252.
12. Charlton M. Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl 2003; 9 (Suppl 3):S58-S62.
13. Foxton MR, Quaglia A, Muiesan P, et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2006; 6:1922-1929.
14. Samonakis DN, Triantos CK, Thalheimer U, et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005; 11:384-385.
15. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003; 9:S63-S66.
16. McCaughan GW, Zekry A. Mechanisms of HCV reinfection and allograft damage after liver transplantation. J Hepatol 2004; 40:368-374.
17. Eason JD, Nair S, Cohen AJ, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003; 75:1396-1399.
18. Brillanti S, Vivarelli M, De Ruvo N, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002; 8:884-888.
19. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32:673-684.
20. Berenguer M, Prieto M, Córdoba J, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998; 28:756-763.
21. Charlton M. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5:S107-S114.
22. Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38:1282-1288.
23. Berenguer M, Rayuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007; 13:21-29. This is a meta-analysis of prospective studies comparing tacrolimus versus CsA-based immunosuppression concerning posttransplantation outcome in HCV-infected recipients showing no differences in patient or graft survival.
24. Berenguer M, Aguilera V, Prieto M, et al. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl 2006; 12:762-767.
25. Martin P, Busuttil RW, Goldstein RM, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis C: a prospective randomized trial. Liver Transpl 2004; 10:1258-1262.
26. Zekry A, Gleeson M, Turhan S, McCaughan GW. The effect of mycophenolate compared to azathioprine on viral load in HCV liver transplant recipients. Liver Transpl 2004; 10:52-58.
27. Nelson DR, Soldevila-Pico C, Reed A, et al. The effect of antiinterleukin-2 receptor therapy on the course of hepatitis C recurrence after liver transplantation. Liver Transpl 2001; 7:1064-1070.
28. Jain A, Kashyap R, Demetris AJ, et al. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002; 8:40-46.
29. Fasola CG, Netto GJ, Christensen LL, et al. Lower incidence of early HCV RNA levels and HCV recurrence postliver transplantation in patients induced with mycophenolate mofetil: a high-dose benefit. Am J Transplant 2002; 2:196.
30. Hunt J, Gordon FD, Lewis WD, et al. Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: influence of immunosuppressive regimens. Liver Transpl 2001; 7:1056-1063.
31. Iacob S, Cicinnati VR, Hilgard P, et al. Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation. Transplantation 2007; 84:56-63.
32. Calmus Y, Scheele JR, Gonzalez-Pinto I, et al. Immunoprophylaxis with basiliximab, a chimeric antiinterleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002; 8:123-131.
33. Neuhaus P, Clavien PA, Kittur D, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002; 8:132-142.
34. Samonakis DN, Cholongitas E, Triantos CK, et al. Sustained, spontaneous disappearance of serum HCV-RNA under immunosuppression after liver transplantation for HCV cirrhosis. J Hepatol 2005; 43:1091-1093.
35. Marcos A, Eghtesad B, Fung JJ, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004; 78:966-971.
36. Filipponi F, Callea F, Salizzoni M, et al. Double-blind comparison of hepatitis C histological recurrence rate in HCV+ liver transplant recipients given basiliximab+steroids or basiliximab+placebo, in addition to cyclosporine and azathioprine. Transplantation 2004; 78:1488-1495.
37. Margarit C, Bilbao I, Castells L, et al. A prospective randomized trial comparing tacrolimus and steroids with tacrolimusmonotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transpl Int 2005; 18:1336-1345.
38. Nair S, Loss GE, Cohen AJ, Eason JD. Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: impact on recurrent hepatitis C virus infection. Transplantation 2006; 81:620-622.
39. Tisone G, Angelico M, Palmieri G, et al. A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation. Transplantation 1999; 67:1308-1313.
40. Ringe B, Braun F, Schütz E, et al. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation 2001; 71:508-515.
41. Samonakis DN, Mela M, Quaglia A, et al. Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis. Transpl Infect Dis 2006; 8:3-12. This paper describes the only prospective study that has evaluated the potential impact of modifying immunosuppression to improve outcome in HCV-infected recipients.
42. Lladó L, Xiol X, Figueras J, et al. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. J Hepatol 2006; 44:710-716.
43. Berenguer M, Aguilera V, Prieto M, et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006; 44:717-722. This paper describes the only prospective study that has evaluated the potential impact of modifying immunosuppression to improve outcome in HCV-infected recipients.
44. Regev A, Molina E, Moura R, et al. Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transpl 2004; 10:1233-1239.
45. Tisone G, Orlando G, Cardillo A, et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 2006; 44:702-709. In the first study on complete immunosuppression withdrawal targeted to HCV recipients, after a mean follow-up 45.5±5.8 months, weaned patients (n=8) showed stabilization/improvement of histological fibrosis (P<0.01), lower necro-inflammation (P<0.02) and improved liver function (P<0.05) compared with weaning-intolerant patients.
46. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant 2006; 6:1774-1780. This paper is an updated and concise review on the available data regarding complete withdrawal of immunosuppression in liver transplant recipients.